Rare Disease Genome Editing Global Market Report 2025

Description

Rare disease genome editing refers to the application of precise genetic modification technologies to correct or alter disease-causing mutations in patients with rare genetic disorders. This approach restores normal gene function, prevents disease progression, and enables the development of personalized therapeutic solutions for conditions with limited or no treatment options. It targets the root cause of the disease at the DNA level rather than managing symptoms.

The primary technologies used in rare disease genome editing include CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats with CRISPR-associated protein 9), transcription activator-like effector nucleases (TALEN), zinc finger nucleases (ZFN), and others. CRISPR-Cas9 employs a guide RNA and the Cas9 enzyme to precisely cut and modify DNA for therapeutic and research purposes. These technologies are applied to various disease types, including monogenic disorders, multifactorial disorders, and chromosomal disorders, and are used in therapeutic development and research by biotechnology and pharmaceutical companies, academic and government research institutes, and hospitals.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The rare disease genome editing market research report is one of a series of new reports from The Business Research Company that provides rare disease genome editing market statistics, including rare disease genome editing industry global market size, regional shares, competitors with a rare disease genome editing market share, detailed rare disease genome editing market segments, market trends and opportunities, and any further data you may need to thrive in the rare disease genome editing industry. This rare disease genome editing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.'

The rare disease genome editing market size has grown rapidly in recent years. It will grow from $1.09 billion in 2024 to $1.29 billion in 2025 at a compound annual growth rate (CAGR) of 17.9%. The growth during the historic period was driven by increasing government funding for genetic research, rising awareness of rare disease diagnosis, growing collaboration between biotech companies, and expanding investment in personalized medicine.

The rare disease genome editing market size is expected to see rapid growth in the next few years. It will grow to $2.46 billion in 2029 at a compound annual growth rate (CAGR) of 17.6%. The growth during the forecast period is fueled by increasing integration of artificial intelligence in genome editing, rising demand for targeted therapies, advancements in gene delivery systems, growing prevalence of multi-gene disorders, and heightened focus on pediatric rare diseases. The primary trends in the forecast period include development of multi-gene editing techniques, integration of AI-driven genomic analysis, technology-enabled personalized gene therapies, innovations in in vivo gene delivery systems, and advancements in high-throughput genome screening.

The growing emphasis on precision medicine is expected to drive the expansion of the rare disease genome editing market. Precision medicine involves tailoring prevention, diagnosis, and treatment strategies based on an individual's genetic makeup, environment, and lifestyle. The increasing focus on this approach is fueled by advances in genomic sequencing and biomarker identification, which enable more accurate detection and targeted therapies. The rare disease genome editing market plays a key role in precision medicine by enabling the precise correction of genetic mutations, making treatments more personalized and effective. This approach addresses the root causes of rare disorders, improving patient outcomes and reducing reliance on symptom-based treatments. For example, in March 2024, Novotech, an Australia-based biotechnology company, reported that 43% of the 217 FDA-approved oncology therapies in 2023 were precision oncology treatments, with 78 of these incorporating DNA or NGS-detectable biomarkers. This growing focus on precision medicine is contributing to the growth of the rare disease genome editing market.

Companies in the rare disease genome editing market are advancing therapeutic platforms, particularly CRISPR-based gene editing systems, to enhance treatment precision and improve outcomes for previously untreatable genetic diseases. CRISPR-based gene editing systems are cutting-edge technologies that allow for precise alterations to the genome, enabling the correction of genetic defects or the introduction of therapeutic genes into cells. For example, in December 2023, Vertex Pharmaceuticals Inc., a US-based biopharmaceutical company, partnered with CRISPR Therapeutics Inc. and received conditional marketing authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for CASGEVY (exagamglogene autotemcel, exa-cel). CASGEVY is indicated for patients aged 12 and older with sickle cell disease (SCD) and recurrent vaso-occlusive crises or transfusion-dependent beta-thalassemia (TDT). The treatment works by editing a patient's hematopoietic stem cells to reactivate fetal hemoglobin production, potentially reducing or eliminating disease symptoms and offering a functional cure for these conditions.

In November 2022, Alexion Pharmaceuticals Inc., a subsidiary of AstraZeneca, acquired LogicBio Therapeutics Inc. for an undisclosed amount. This acquisition allows Alexion to expand its presence in the field of rare disease genomics and leverage LogicBio's GeneRide platform to develop innovative therapies. LogicBio Therapeutics is a clinical-stage company specializing in genome-editing therapies for rare genetic disorders.

Major players in the rare disease genome editing market are Regeneron Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ultragenyx Pharmaceutical Inc., Beam Therapeutics Inc., CRISPR Therapeutics AG, Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., Arcturus Therapeutics Holdings Inc., Editas Medicine Inc., Krystal Biotech Inc., Caribou Biosciences Inc, Bluebird Bio Inc., SpliceBio S.L., Cellectis SA, Generation Bio Co., iECURE Inc., Affinia Therapeutics Inc., Precision Biosciences Inc., Intellia Therapeutics Inc., and MeiraGTx Holdings plc.

North America was the largest region in the rare disease genome editing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in rare disease genome editing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the rare disease genome editing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rare disease genome editing market consists of revenues earned by entities by providing services such as gene editing therapy development, genetic testing and diagnostics, preclinical research and validation, clinical trial management, and regulatory consulting for genome-based therapeutics. The market value includes the value of related goods sold by the service provider or included within the service offering. The rare disease genome editing market also includes sales of zinc finger nucleases, delivery vectors, modified cells, and therapeutic genome-editing formulations. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Rare Disease Genome Editing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rare disease genome editing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for rare disease genome editing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The rare disease genome editing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Technology: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9; Transcription Activator-Like Effector Nucleases (TALEN); Zinc Finger Nucleases (ZFN); Other Technologies
2) By Disease Type: Monogenic Disorders; Multifactorial Disorders; Chromosomal Disorders
3) By Application: Therapeutics; Research
4) By End User: Biotechnology And Pharmaceutical Companies; Academic And Government Research Institutes; Hospitals
Subsegments:
1) By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 9; Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 12; Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 13; Base Editing; Prime Editing
2) By Transcription Activator-Like Effector Nucleases (TALEN): Standard Transcription Activator-Like Effector Nucleases (TALEN); Designer Transcription Activator-Like Effector Nucleases (dTALEN); Transcription Activator-Like Effector Nucleases (TALEN) Paired Nucleases
3) By Zinc Finger Nucleases (ZFN): Standard Zinc Finger Nucleases (ZFN); Engineered Zinc Finger Nucleases (ZFN); Modular Zinc Finger Nucleases (ZFN)
4) By Other Technologies: Meganucleases; Ribonucleic Acid (RNA)-Guided Nucleases; Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Transposases
Companies Mentioned: Regeneron Pharmaceuticals Inc.; Sarepta Therapeutics Inc.; Ultragenyx Pharmaceutical Inc.; Beam Therapeutics Inc.; CRISPR Therapeutics AG; Rocket Pharmaceuticals Inc.; Sangamo Therapeutics Inc.; Arcturus Therapeutics Holdings Inc.; Editas Medicine Inc.; Krystal Biotech Inc.; Caribou Biosciences Inc; Bluebird Bio Inc.; SpliceBio S.L.; Cellectis SA; Generation Bio Co.; iECURE Inc.; Affinia Therapeutics Inc.; Precision Biosciences Inc.; Intellia Therapeutics Inc.; MeiraGTx Holdings plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r38619

1. Executive Summary

2. Rare Disease Genome Editing Market Characteristics

3. Rare Disease Genome Editing Market Trends And Strategies

4. Rare Disease Genome Editing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Rare Disease Genome Editing Growth Analysis And Strategic Analysis Framework

5.1. Global Rare Disease Genome Editing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Rare Disease Genome Editing Market Growth Rate Analysis
5.4. Global Rare Disease Genome Editing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Rare Disease Genome Editing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Rare Disease Genome Editing Total Addressable Market (TAM)

6. Rare Disease Genome Editing Market Segmentation

6.1. Global Rare Disease Genome Editing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9
Transcription Activator-Like Effector Nucleases (TALEN)
Zinc Finger Nucleases (ZFN)
Other Technologies
6.2. Global Rare Disease Genome Editing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monogenic Disorders
Multifactorial Disorders
Chromosomal Disorders
6.3. Global Rare Disease Genome Editing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Therapeutics
Research
6.4. Global Rare Disease Genome Editing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Biotechnology And Pharmaceutical Companies
Academic And Government Research Institutes
Hospitals
6.5. Global Rare Disease Genome Editing Market, Sub-Segmentation Of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 9
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 12
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 13
Base Editing
Prime Editing
6.6. Global Rare Disease Genome Editing Market, Sub-Segmentation Of Transcription Activator-Like Effector Nucleases (TALEN), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Standard Transcription Activator-Like Effector Nucleases (TALEN)
Designer Transcription Activator-Like Effector Nucleases (dTALEN)
Transcription Activator-Like Effector Nucleases (TALEN) Paired Nucleases
6.7. Global Rare Disease Genome Editing Market, Sub-Segmentation Of Zinc Finger Nucleases (ZFN), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Standard Zinc Finger Nucleases (ZFN)
Engineered Zinc Finger Nucleases (ZFN)
Modular Zinc Finger Nucleases (ZFN)
6.8. Global Rare Disease Genome Editing Market, Sub-Segmentation Of Other Technologies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Meganucleases
Ribonucleic Acid (RNA)-Guided Nucleases
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Transposases

7. Rare Disease Genome Editing Market Regional And Country Analysis

7.1. Global Rare Disease Genome Editing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Rare Disease Genome Editing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Rare Disease Genome Editing Market

8.1. Asia-Pacific Rare Disease Genome Editing Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Rare Disease Genome Editing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Rare Disease Genome Editing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Rare Disease Genome Editing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Rare Disease Genome Editing Market

9.1. China Rare Disease Genome Editing Market Overview
9.2. China Rare Disease Genome Editing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Rare Disease Genome Editing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Rare Disease Genome Editing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Rare Disease Genome Editing Market

10.1. India Rare Disease Genome Editing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Rare Disease Genome Editing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Rare Disease Genome Editing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Rare Disease Genome Editing Market

11.1. Japan Rare Disease Genome Editing Market Overview
11.2. Japan Rare Disease Genome Editing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Rare Disease Genome Editing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Rare Disease Genome Editing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Rare Disease Genome Editing Market

12.1. Australia Rare Disease Genome Editing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Rare Disease Genome Editing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Rare Disease Genome Editing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Rare Disease Genome Editing Market

13.1. Indonesia Rare Disease Genome Editing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Rare Disease Genome Editing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Rare Disease Genome Editing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Rare Disease Genome Editing Market

14.1. South Korea Rare Disease Genome Editing Market Overview
14.2. South Korea Rare Disease Genome Editing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Rare Disease Genome Editing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Rare Disease Genome Editing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Rare Disease Genome Editing Market

15.1. Western Europe Rare Disease Genome Editing Market Overview
15.2. Western Europe Rare Disease Genome Editing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Rare Disease Genome Editing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Rare Disease Genome Editing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Rare Disease Genome Editing Market

16.1. UK Rare Disease Genome Editing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Rare Disease Genome Editing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Rare Disease Genome Editing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Rare Disease Genome Editing Market

17.1. Germany Rare Disease Genome Editing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Rare Disease Genome Editing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Rare Disease Genome Editing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Rare Disease Genome Editing Market

18.1. France Rare Disease Genome Editing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Rare Disease Genome Editing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Rare Disease Genome Editing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Rare Disease Genome Editing Market

19.1. Italy Rare Disease Genome Editing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Rare Disease Genome Editing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Rare Disease Genome Editing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Rare Disease Genome Editing Market

20.1. Spain Rare Disease Genome Editing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Rare Disease Genome Editing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Rare Disease Genome Editing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Rare Disease Genome Editing Market

21.1. Eastern Europe Rare Disease Genome Editing Market Overview
21.2. Eastern Europe Rare Disease Genome Editing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Rare Disease Genome Editing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Rare Disease Genome Editing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Rare Disease Genome Editing Market

22.1. Russia Rare Disease Genome Editing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Rare Disease Genome Editing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Rare Disease Genome Editing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Rare Disease Genome Editing Market

23.1. North America Rare Disease Genome Editing Market Overview
23.2. North America Rare Disease Genome Editing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Rare Disease Genome Editing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Rare Disease Genome Editing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Rare Disease Genome Editing Market

24.1. USA Rare Disease Genome Editing Market Overview
24.2. USA Rare Disease Genome Editing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Rare Disease Genome Editing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Rare Disease Genome Editing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Rare Disease Genome Editing Market

25.1. Canada Rare Disease Genome Editing Market Overview
25.2. Canada Rare Disease Genome Editing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Rare Disease Genome Editing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Rare Disease Genome Editing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Rare Disease Genome Editing Market

26.1. South America Rare Disease Genome Editing Market Overview
26.2. South America Rare Disease Genome Editing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Rare Disease Genome Editing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Rare Disease Genome Editing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Rare Disease Genome Editing Market

27.1. Brazil Rare Disease Genome Editing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Rare Disease Genome Editing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Rare Disease Genome Editing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Rare Disease Genome Editing Market

28.1. Middle East Rare Disease Genome Editing Market Overview
28.2. Middle East Rare Disease Genome Editing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Rare Disease Genome Editing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Rare Disease Genome Editing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Rare Disease Genome Editing Market

29.1. Africa Rare Disease Genome Editing Market Overview
29.2. Africa Rare Disease Genome Editing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Rare Disease Genome Editing Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Rare Disease Genome Editing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Rare Disease Genome Editing Market Competitive Landscape And Company Profiles

30.1. Rare Disease Genome Editing Market Competitive Landscape
30.2. Rare Disease Genome Editing Market Company Profiles
- 30.2.1. Regeneron Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Sarepta Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Ultragenyx Pharmaceutical Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Beam Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. CRISPR Therapeutics AG Overview, Products and Services, Strategy and Financial Analysis

31. Rare Disease Genome Editing Market Other Major And Innovative Companies

31.1. Rocket Pharmaceuticals Inc.
31.2. Sangamo Therapeutics Inc.
31.3. Arcturus Therapeutics Holdings Inc.
31.4. Editas Medicine Inc.
31.5. Krystal Biotech Inc.
31.6. Caribou Biosciences Inc
31.7. Bluebird Bio Inc.
31.8. SpliceBio S.L.
31.9. Cellectis SA
31.10. Generation Bio Co.
31.11. iECURE Inc.
31.12. Affinia Therapeutics Inc.
31.13. Precision Biosciences Inc.
31.14. Intellia Therapeutics Inc.
31.15. MeiraGTx Holdings plc

32. Global Rare Disease Genome Editing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Rare Disease Genome Editing Market

34. Recent Developments In The Rare Disease Genome Editing Market

35. Rare Disease Genome Editing Market High Potential Countries, Segments and Strategies

35.1 Rare Disease Genome Editing Market In 2029 - Countries Offering Most New Opportunities
35.2 Rare Disease Genome Editing Market In 2029 - Segments Offering Most New Opportunities
35.3 Rare Disease Genome Editing Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer